Surveillance for Adverse Events After COVID-19 mRNA Vaccination
Open Access
- 3 September 2021
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA
- Vol. 326 (14), 1390-1399
- https://doi.org/10.1001/jama.2021.15072
Abstract
Safe and effective vaccines against SARS-CoV-2 are critical to ending the pandemic. Two messenger RNA (mRNA) vaccines (BNT162b2, Pfizer-BioNTech; and mRNA-1273, Moderna) were the first SARS-CoV-2 vaccines authorized in the US.1,2 Large phase 3 trials for BNT162b2 and mRNA-1273 demonstrated that both vaccines were more than 94% effective against symptomatic SARS-CoV-2 infection.3,4 Neither trial reported serious safety findings, and both observed low incidence of serious adverse events.Keywords
This publication has 33 references indexed in Scilit:
- Statistics in MedicineStatistics in Medicine, 2016
- Risk of anaphylaxis after vaccination in children and adultsJournal of Allergy and Clinical Immunology, 2015
- Risk of Intussusception after Monovalent Rotavirus VaccinationThe New England Journal of Medicine, 2014
- H1N1 and Seasonal Influenza Vaccine Safety in the Vaccine Safety Datalink ProjectAmerican Journal of Preventive Medicine, 2011
- The Vaccine Safety Datalink: A Model for Monitoring Immunization SafetyPEDIATRICS, 2011
- Measles-Mumps-Rubella-Varicella Combination Vaccine and the Risk of Febrile SeizuresPEDIATRICS, 2010
- Real-Time Vaccine Safety Surveillance for the Early Detection of Adverse EventsMedical Care, 2007
- Anaphylaxis: Case definition and guidelines for data collection, analysis, and presentation of immunization safety dataVaccine, 2007
- Spatial disease clusters: Detection and inferenceStatistics in Medicine, 1995
- Group sequential methods in the design and analysis of clinical trialsBiometrika, 1977